Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Prime Movers Lab
Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies
May 18, 2026
Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder
January 9, 2026